Definium Therapeutics (DFTX) Other Operating Expenses (2019 - 2025)
Definium Therapeutics (DFTX) reported Other Operating Expenses of -$35000.0 for Q4 2025, down 1066.67% year-over-year from $3620.7 in Q4 2024, and down 1066.67% on a QoQ basis from -$3000.0 in Q4 2024.
Definium Therapeutics (DFTX) has 4 years of Other Operating Expenses data on file, last reported at -$35000.0 in Q4 2025.
- Quarterly Other Operating Expenses fell 1066.67% year-over-year to -$35000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$35000.0 (down 1066.67% YoY) and the FY2025 annual result came in at -$35000.0, down 1066.67% from the prior year.
- Other Operating Expenses eased to -$35000.0 in Q4 2025 per DFTX's latest filing, from -$3000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at -$3000.0 in Q4 2024 and bottomed at -$35000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -35,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2020 | 7.25 Mn |
| Sep 30, 2020 | 700,000.00 |
| Jun 30, 2020 | 1.45 Mn |
| Dec 31, 2019 | 7.13 Mn |